ANDA 77761, held by Hikma Farmacêutica. Metoprolol Tartrate.
As of Nov 22, 2026, ANDA 77761 (Metoprolol Tartrate), held by Hikma Farmacêutica, was first approved by FDA on May 30, 2007, with 7 approved supplements and 0 published complete response letters.
Metoprolol Tartrate Injection, USP is indicated in the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy. Metoprolol Tartrate Injection is a beta-adrenergic receptor inhibitor indicated for the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 30, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metoprolol Tartrate1MG/ML · injectable;injection | Metoprolol Tartrate | Rx |
| Mar 24, 2025 | Supplement 26Labeling · Standard review | Approved | None posted |
| Jan 7, 2022 | Supplement 24Labeling · Standard review | Approved | None posted |
| Nov 12, 2015 | Supplement 16Labeling · Standard review | Approved | None posted |
| Feb 27, 2013 | Supplement 13Labeling | Approved | None posted |
| Feb 26, 2010 | Supplement 10Labeling | Approved | None posted |
| Jan 19, 2010 | Supplement 9Labeling | Approved | None posted |
| Feb 26, 2009 | Supplement 6Labeling | Approved | None posted |
| May 30, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters